Clinical Trials Logo

Primary Membranous Nephropathy clinical trials

View clinical trials related to Primary Membranous Nephropathy.

Filter by:

NCT ID: NCT06466135 Not yet recruiting - Clinical trials for Diabetic Nephropathies

Study of WAL0921 in Patients With Glomerular Kidney Diseases

Start date: June 17, 2024
Phase: Phase 2
Study type: Interventional

This is an adaptive prospective, multi-center, randomized, double-blind, placebo-controlled study to evaluate the safety, efficacy, pharmacokinetics, and pharmacodynamics of WAL0921 in subjects with glomerular kidney disease and proteinuria, including diabetic nephropathy and rare glomerular kidney diseases (primary focal segmental glomerulosclerosis [FSGS], treatment-resistant minimal change disease [TR MCD], primary immunoglobulin A nephropathy [IgAN], and primary membranous nephropathy [PMN]). Subjects in this study will be randomized to receive the investigational drug WAL0921 or placebo as an intravenous infusion once every 2 weeks for 7 total infusions. All subjects will be followed for 24 weeks after their last infusion.

NCT ID: NCT06120673 Not yet recruiting - Clinical trials for Primary Membranous Nephropathy

REmission in Membranous Nephropathy International Trial (REMIT)

REMIT
Start date: July 31, 2024
Phase: Phase 3
Study type: Interventional

REMIT is an investigator-initiated, international, multi-centre, prospective, randomised, open-label, parallel-group trial. A total of 224 adult participants with Primary Membranous Nephropathy (PMN) will be recruited from renal units from Australia, New Zealand Canada, Asia, Europe, United Kingdom, and other countries. Participants will be randomised to receive either corticosteroid and cyclophosphamide or obinutuzumab. The primary outcome is a ranked, composite measure based on (a) efficacy, defined as either complete or partial remission of PMN, (b) number of adverse events, and (c) quality of life.

NCT ID: NCT05862233 Recruiting - Clinical trials for Primary Membranous Nephropathy

A Clinical Study of MIL62 in Primary Membranous Nephropathy

Start date: June 2, 2023
Phase: Phase 3
Study type: Interventional

This study will evaluate the efficacy, safety, pharmacokinetics(PK) ,pharmacodynamics and anti-drug antibodies(ADA) of MIL62 compared with cyclosporine in participants with primary membranous nephropathy (pMN).

NCT ID: NCT05800873 Recruiting - Clinical trials for Primary Membranous Nephropathy

Evaluate The Efficacy, Safety, Pharmacokinetics And Pharmacodynamics Of EVER001

Start date: May 15, 2023
Phase: Phase 1
Study type: Interventional

EVER001 is a highly selective, oral, reversable, covalent Bruton tyrosine kinase (BTK) inhibitor with high selectivity over other kinases, which is being developed to treat proteinuric glomerular diseases. The overall aim of the study is to evaluate the efficacy, safety, pharmacokinetics and pharmacodynamics of EVER001 in subjects with selected proteinuric glomerular diseases. The first targeted is primary membranous nephropathy.

NCT ID: NCT05707377 Recruiting - Clinical trials for Primary Membranous Nephropathy

A Study to Evaluate the Safety and Efficacy of Zanubrutinib in Participants With Primary Membranous Nephropathy

Start date: April 17, 2023
Phase: Phase 2/Phase 3
Study type: Interventional

The primary objectives of this study are: In Part 1 to evaluate the efficacy of zanubrutinib as measured by proteinuria reduction, and in Part 2 to evaluate the efficacy of zanubrutinib compared with tacrolimus as measured by complete remission rate, in participants with primary membranous nephropathy who are on optimal supportive care.

NCT ID: NCT05696613 Recruiting - Clinical trials for Primary Membranous Nephropathy

A Study of SNP-ACTH (1-39) Gel in Patients With Primary Membranous Nephropathy

Start date: March 13, 2023
Phase: Phase 3
Study type: Interventional

The goal of the Phase 3a part of this clinical trial is to determine the optimal dose that will be used in the Phase 3b part of this clinical trial. The goal of the Phase 3b part is to assess the efficacy of SNP-ACTH (1-39) Gel relative to rituximab in patients with primary membranous nephropathy (PMN) at month 24.

NCT ID: NCT05668403 Recruiting - Clinical trials for Primary Membranous Nephropathy

A Phase I Clinical Study of Recombinant Humanized Anti-CD20(B-lymphocyte Antigen CD20) Monoclonal Antibody Subcutaneous Injection in the Treatment of Primary Membranous Nephropathy

Start date: March 2, 2023
Phase: Phase 1
Study type: Interventional

This Phase I Clinical Study assessed the Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Profiles and Preliminary Efficacy of Subcutaneous Injection of Recombinant Humanized Anti-CD20 Monoclonal Antibody in the Treatment of Primary Membranous Nephropathy

NCT ID: NCT05514015 Recruiting - Clinical trials for Primary Membranous Nephropathy

Clinical Study of Rituximab Combined With Corticosteroids or Rituximab Monotherapy in the Treatment of Primary Membranous Nephropathy

Start date: March 29, 2024
Phase: Phase 4
Study type: Interventional

This was a prospective, randomized, multicenter clinical trial. Seventy-eight patients with primary membranous nephropathy (PMN) were randomly divided into intervention or control group. Intervention group was given rituximab combined with corticosteroids in induction therapy and the control group was given rituximab monotherapy. After 6 months, patients who had decreased 24h urinary protein by > 25% but did not achieve CR were given rituximab maintenance therapy. The complete response rate at 12 months was measured.

NCT ID: NCT05398653 Recruiting - Clinical trials for Primary Membranous Nephropathy

A Clinical Study of MIL62 in Primary Membranous Nephropathy

Start date: February 24, 2022
Phase: Phase 1/Phase 2
Study type: Interventional

This study was divided into two stages. In the first stage (Phase Ib), 30 subjects were randomly divided into MIL62 600mg, MIL62 1000mg and cyclosporine groups at a ratio of 1:1:1, with 10 subjects in each group. Tolerance to MIL62 was evaluated within 4 weeks after the first administration. If the overall safety is determined by the investigator and sponsor to be tolerable to MIL62, phase II enrollment will be initiated. The second stage was also randomly divided into MIL62 600mg, MIL62 1000mg and cyclosporine groups according to the ratio of 1:1:1, 30 subjects in each group, to evaluate the efficacy of MIL62 and cyclosporine in the treatment of primary membranous nephropathy. Eligible subjects in both phases received treatment and follow-up for a total of 104 weeks. The 76-week overall response rate was the primary endpoint.

NCT ID: NCT05136456 Active, not recruiting - Clinical trials for Primary Membranous Nephropathy

Evaluate the Efficacy and Safety of SHR1459 Tablets in Patients With Primary Membranous Nephropathy

Start date: December 15, 2021
Phase: Phase 2
Study type: Interventional

The purpose of this study is to evaluate the efficacy and safety of SHR1459 tablets in patients with primary membranous nephropathy.